ArticleDiabetology & metabolic syndrome2025
Triglyceride-glucose index, a silent predictor for osteosarcopenic adiposity occurrence and risk of cardiovascular and all-cause mortality.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe evidence linking the triglyceride-glucose (TyG) index to osteosarcopenic adiposity (OSA) in young and middle-aged populations is limited. This study aimed to investigate the association between the TyG index and OSA, and to determine the predictive value of the TyG index for all-cause and cardiovascular disease (CVD) mortality in OSA patients.
methodsThis cross-sectional and cohort study enrolled 8,098 participants aged 20-59 in the National Health and Nutrition Examination Survey (1999-2006 and 2011-2018). Mortality was determined by linkage to the National Death Index through December 31, 2019. Multivariable logistic regression models and restricted cubic splines (RCS) were constructed to determine the association between the TyG index and the prevalence of OSA. Multivariable Cox proportional hazards regression and competing risk analyses were employed to evaluate the association between the TyG index and mortality among OSA patients.
resultsThere were 4,153 participants in the 1999-2006 cycle (weighted proportion male, 50.8%; mean [SD] age, 39.53 [10.98] years), and 3,945 in the 2011-2018 cycle (weighted proportion male, 50.7%; mean [SD] age, 39.00 [11.72] years). A higher TyG index was significantly associated with a greater prevalence of OSA, with an odds ratio (OR) of 4.52 (95% confidence interval [CI]: 3.78, 5.42) for the highest quartile. A J-shaped association was identified between the TyG index and the prevalence of OSA. Additionally, during a mean follow-up period of 131.1 months, OSA patients with the TyG index ≥ 8.5 exhibited a significantly elevated risk of all-cause mortality (hazard ratio [HR] = 1.93, 95% CI: 1.37, 2.71) and CVD mortality (HR = 2.10, 95% CI: 1.13, 3.88). Furthermore, sex disparity markedly affected the association between the TyG index and the prevalence of OSA and all-cause mortality in OSA patients.
conclusionsThis study revealed that a higher TyG index was associated with an increased risk of OSA and predicted a higher all-cause and CVD mortality in OSA patients. The implementation of public health interventions to reduce the TyG index may prove an effective method to decrease the incidence of OSA and related mortalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.